Synexus finalises acquisition of ClinPharm at the start of 2010

Following their recent announcement of the deal to acquire German company, ClinPharm, Manchester-based Synexus is celebrating the start of 2010 with the news that the acquisition has now been finalised. This increases the number of Synexus dedicated research centres to twenty-six.

Synexus is the world’s largest multi-national company entirely focussed on the recruitment and running of clinical trials at its own Dedicated Research Centres. While it has a network of research centres in Central and Eastern Europe, this deal adds eight research centres in Germany and strengthens the company’s Central and Eastern Europe portfolio of centres in Poland, Hungary and Bulgaria with additional sites in Austria and Ukraine. Synexus now has research centres in Western, Central and Eastern Europe, South Africa and Asia.

The ClinPharm acquisition increases Synexus’ total patient population reach to over 30 million patients; an increase of 50 per cent globally and 100 per cent across Europe. No other patient recruitment organisation can compete in terms of size or scale. ClinPharm also brings considerable additional therapy area experience to Synexus.

This acquisition follows a period of considerable growth for Synexus and Chief Executive Michael Fort says this is only the start: “We have had a very successful 2009, increasing our presence not only throughout Europe but also in South Africa, another very important region for future growth. We certainly won’t be resting on our laurels in 2010, we are expecting significant developments in relation to India and China, two countries where the clinical trials market is growing incredibly fast and we plan on being an important part of that.”